ArticleBiomedical reports2025
Expression of Oct3/4 isoforms and its association with the risk of relapse in acute lymphoblastic leukemia.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Measurable Residual Disease and the Unresolved Biology of Leukemic Stem Cells.Stem cell reviews and reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oct3/4 is a transcription factor that maintains the stemness of both embryonic and adult stem cells. The Oct3/4 gene produces three isoforms: namely, Oct3/4A, Oct3/4B and Oct3/4B1. Increased Oct3/4 expression is associated with lower survival rates and chemoresistance in patients with cancer. The present study examined the association between Oct3/4 isoforms expression and the risk of relapse to acute lymphoblastic leukemia (ALL). The mRNA expression levels of Oct3/4A, Oct3/4B and Oct3/4B1 were analyzed using reverse transcription-quantitative PCR in 51 patients with ALL and 12 children without ALL. The results of the present study indicated that the mRNA expression levels of Oct3/4A (P=0.008), Oct3/4B (P=0.019) and Oct3/4B1 (P=0.025) were significantly elevated in patients with ALL. Moreover, elevated mRNA expression levels of Oct3/4A [odds ratio (OR)=13.33; 95% confidence interval (CI): 1.57-112.99; P=0.018), Oct3/4B (OR=20.00; 95% CI: 2.37-168.64; P=0.006) and Oct3/4B1 (OR=7.26, 95% CI: 1.43-36.93; P=0.017) isoforms were associated with a heightened risk of relapse in patients with ALL. The multivariate analysis, stratified using established prognostic factors, identified Oct3/4A, Oct3/4B and Oct3/4B1 mRNA expression levels as independent prognostic markers of ALL. The results of the present study also indicated that the expression levels of Oct3/4A (P=0.0112), Oct3/4B (P=0.0044) and Oct3/4B1 (P=0.0071) were significantly elevated in CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.